Page 28 - 84_04

Obesity: a risk for Alzheimer's disease? II. Connecting therapies
mouse model. PLoSOne 2013;8(3):e58784.
91. Parthsarathy V, Holscher C. The type 2 diabetes drug
liraglutide reduces chronic inflammation induced by
irradiation in the mouse brain. Eur J Pharmacol
2013;700(1-3):42-50.
92. Holscher C. The incretin hormones GLP1 and glucose-
dependent insulinotropic polypeptide are
neuroprotective in mouse models of Alzheimer’s
disease. Alzheimers Dement 2014;10(1Suppl):S47-54.
93. Wilding JP, Hardy K. Glucagon-like peptide-1
analogues for type 2 diabetes. BMJ 2011;342:d410.
94. Ashby EL, Kehoe P. Current status of renin-
aldosterone angiotensin system-targeting anti-
hypertensive drugs as therapeutic options for AD.
Expert Opin Investig Drugs 2013;22(10):1229-42.
95. Kurinami H, Shimamura M, Sato N, Nakagami H,
Morishita R. Do angiotensin receptor blockers protect
against Alzheimer's disease? Drugs Aging
2013;30(6):367-72.
96. Anekonda TS, Quinn JF. Calcium channel blocking as
a therapeutic strategy for Alzheimer's disease: the case
for isradipine. Biochim Biophys Acta
2011;1812(12):1584-90.
97. Hanyu H, Hirao K, Shimizu S, Iwamoto T, Koizumi K,
Abe K. Favourable effects of nilvadipine on cognitive
function and regional cerebral blood flow on SPECT
in hypertensive patients with MCI. Nucl Med
Commun 2007;28(4):281-7.
98. Yong VW, Wells J, Giuliani F, Casha S, Power C,
Metz LM. The promise of minocycline in neurology.
Lancet Neurol 2004;3(12):744-51.
99. Chen SD, Yin JH, Hwang CS, Tang CM, Yang DI.
Anti-apoptotic and anti-oxidative mechanisms of
minocycline against sphingomyelinase/ ceramide
neurotoxicity: implication in AD and cerebral
ischemia. Free Radic Res 2012;46(8):940-50.
100. Cai Z, Yan Y, Wang Y. Minocycline alleviates beta-
amyloid protein and tau pathology via restraining
neuroinflammation induced by diabetic metabolic
disorder. Clin Interv Aging 2013;8:1089-95.
101. Ferretti MT, Allard S, Partridge V, Ducatenzeiler A,
Cuello AC. Minocycline corrects early, pre-plaque
neuroinflammation and inhibits BACE-1 in a
transgenic model of AD-like amyloid pathology. J
Neuroinflammation 2012;9:62.
102. Lerner AJ, Gustaw-Rothenberg K, Smyth S,
Casadesus G. Retinoids for treatment of Alzheimer's
disease. Biofactors 2012;38(2):84-9.
103. Carratù MR, Marasco C, Signorile A, Scuderi C,
Steardo L. Are retinoids a promise for AD
management? Curr Med Chem 2012;19(36):6119-25.
104. Wang J, Tan L, Wang HF, Tan CC, Meng XF, Wang
C, Tang SW, Yu JT. Anti-inflammatory drugs and risk
of Alzheimer's disease: an updated systematic review
and meta-analysis. J Alzheimers Dis 2015;44(2):385-
96.
105. Szekely CA, Zandi PP. Non-steroidal anti-
inflammatory drugs and Alzheimer's disease: the
epidemiological evidence. CNS Neurol Disord Drug
@Real Academia Nacional de Farmacia. Spain
Targets 2010;9(2):132-9.
106. Toledano A, Álvarez MI, Carmona P, De Miguel E.
Immunohistochemical increase in cyclooxygenase-2
without apoptosis in different brain areas of
subchronic nicotine- and D-amphetamine treatment
rat. J. Neural Transm 2008;115(8):1093-108
107. Toledano A, Álvarez MI, Toledano-Díaz A. Diversity
and variability of the nicotine effects on different
brain cortical regions. Therapeutic and toxicologic
implications. Central Nervous System Agents in
Medicinal Chemistry. 2010; 10:180-206.
108. Toledano A, Alvarez MI, Toledano-Díaz A. Multiple
neuronal and glial mechanisms can be involved in the
response to the activation of nicotinic receptors. In: A
Costa , E Villalba (Eds) Horizons in Neuroscience
Research. Volume 3 Neural Transmissions:
Characteristics, Mechanisms and Malfunctioning.
Nova Science Publishers, Inc. Hauppauge, NY 2011;
pp 1-34. ISBN: 978-1-61728-027-6.
109. Frank M. Minimizing the Risk of Alzheimer's
Disease. 2012, NY USA Algora Publishing.
110. Nicolia V, Lucarelli M, Fuso A. Environment,
epigenetics and neurodegeneration: Focus on nutrition
in Alzheimer's disease. Exp Gerontol 2015;68:8-12.
111. Defina LF, Willis BL, Radford NB, Gao A, Leonard
D, Haskell WL, Weiner MF, Berry JD. The
association between midlife cardiorespiratory fitness
levels and later-life dementia: a cohort study. Ann
Intern Med 2013;158(3):162-8.
112. Duzel E, Van Praag H, Sendtner M. Can physical
exercise in old age improve memory and hippocampal
function? Brain 2016;139(3):662-73.
113. Hotting K, Roder B. Beneficial effects of physical
exercise on neuroplasticity and cognition. Neurosci
Biobehav Rev 2013;37(9 Pt B):2243-57.
114. Rodriguez-Casado J, Alvarez MI, De Miguel E,
Toledano A, Carmona P. Amphetamine effects on
oxidative stress and formation of proteic beta-sheet
structures as revealed by FTIR microspectroscopy.
Biopolymers 2007;86:437-446.
115. Hendrie HC, Osuntokun BO, Hall KS, Ogunniyi AO,
Hui SL, Unverzagt FW, et al. Prevalence of
Alzheimer's disease and dementia in two
communities: Nigerian Africans and African
Americans. Am J Psychiatry 1995;152(10):1485-92.
116. Graves AB, Larson EB, Edland SD, Bowen JD,
McCormick WC, McCurry SM, et al. Prevalence of
dementia and its subtypes in the Japanese American
population of King County, Washington state. The
Kame Project. Am J Epidemiol 1996;144(8):760-71.
117. Murray F. Can Alzheimer's disease be prevented?
Intractable Rare Dis Res 2013;2(4):136-8.
118. Kotharia V, Luo Y, Tornabene T, O'Neill AM, Greene
MW, Geetha T, Babu JR. High fat diet induces brain
insulin resistance and cognitive impairment in mice.
Biochim Biophys Acta 2017; 1863:499–508
119. Busquets O, Ettcheto M, Pallàs M, Beaz-Zarate C,
Verdaguer E, Auladell C, et al. Long –term exposition
to a high fat diet favors the appeareance of beta-
357